May 2010
Synthesis of Crown Compounds Containing a 1,3,4-Oxadiazole Moiety:
Microwave-Assisted Synthesis
557
Scheme 2
d (ppm) 3.56 (s, 4H, CH2 (11) and CH2 (12)), 3.56–3.78 (m,
8H, CH2 (9), CH2 (14), CH2 (17) and CH2 (18)), 4.09 (t, J ¼
5.1 Hz, 4H, CH2 (6) and CH2 (17)), 4.38 (t, J ¼ 5.1 Hz, 4H,
CH2 (5) and CH2 (18)), 7.08 (d, J ¼ 7.5 Hz, 2H, 6-H), 7.13
(dd, J ¼ 6.7 Hz, 2H, 4-H), 7.44 (dd, J ¼ 7.0 Hz, 2H, 5-H),
8.54 (d, J ¼ 8.4 Hz, 2H, 3-H). 13C NMR (CDCl3): d (ppm)
60.8 (CH2 (5) and CH2 (18)), 62.6 (CH2 (6) and CH2 (17)),
64.1 (CH2 (8) and CH2 (15)), 64.1 (CH2 (9, 11, 12 and 14),
108.9 (C6), 114.9 (C4), 122.0 (C2), 126.5 (C3), 138.8 (C5),
152.7 (C7), 164.7 (C1-oxadiazole). MALDI-TOF-MS: m/z 457
(M þ 1).
113.5 (C4), 122.5 (C2), 127.2 (C3), 138.6 (C5), 150.1 (C7),
163.4 (C1-oxadiazole). MALDI-TOF-MS: m/z 325 (M þ1).
2,3,14,15-Dibenzo-4,7,10,13,19-pentaoxa-17,18-diazabicy-
1
clo[14.2.1]nonadeca-16,18-diene (2b). H NMR (CDCl3): d
REFERENCES AND NOTES
(ppm) 3.54 (s, 4H, CH2 (8) and CH2 (9)), 3.87–3.91 (m, 4H,
CH2 (6) and CH2 (11)), 4.24–4.28 (m, 4H, CH2 (5) and CH2
(12)), 7.04 (d, J ¼ 8.3 Hz, 2H, 6-H), 7.08 (dd, J ¼ 8.0 Hz,
2H, 4-H), 7.49 (dd, J ¼ 8.0 Hz, 2H, 5-H), 7.90 (d, J ¼ 7.6
Hz, 2H, 3-H). 13C NMR (CDCl3): d (ppm) 60.3 (CH2 (5) and
CH2 (12)), 62.7 (CH2 (8) and CH2 (9)), 73.2 (CH2 (6) and
CH2 (11)), 108.1 (C6), 114.5 (C4), 121.3 (C2), 126.3 (C3),
138.3 (C5), 152.8 (C7), 164.0 (C1-oxadiazole). MALDI-TOF-
MS: m/z 369 (M þ 1).
[1] Lehn, J. M. Angew Chem Int Ed Eng 1988, 27, 89.
[2] Cram, D. J. Angew Chem Int Ed Eng 1988, 27, 1009.
[3] Pedersen, C. J. J Am Chem Soc 1967, 89, 7017.
[4] (a) Bradshaw, J. S.; Chamberlin, D. A.; Harrison, P. E.;
Wilson, B. E.; Arena, G.; Dalley, N. K.; Lamb, J. D.; Izatt, R. M.
J Org Chem 1985, 50, 3065; (b) Bradshaw, J. S.; Nielsen, R. B.; Tse,
P. K.; Arena, G.; Wilson, B. E.; Dalley, N. K.; Lamb, J. D.; Christen-
sen, J. J.; Izatt, R. M.
J Heterocyclic Chem 1986, 23, 361;
(c) Bradshaw, J. S.; McDaniel, C. W. B.; Skidmore, D.; Nielsen, R.
B.; Wilson, B. E.; Dalley, N. K.; Izatt, R. M. J Heterocyclic Chem
1987, 24, 1085; (d) Elshani, S.; Apgar, P.; Wang, S.; Wai, C. M.
J Heterocyclic Chem 1994, 31, 1271; (e) Yang, J.; Li, Z. T.; Hua, W.
T. Youji Huaxue 2001, 21, 467; (f) Hegmann, T.; Neumann, B.; Wolf,
R.; Tschierske, C. J Mat Chem 2005, 15, 1025.
2,3,17,18-Dibenzo-4,7,10,13,16,22-hexaoxa-20,21-diazabicy-
1
clo[17.2.1]docosa-19,21-diene (2c). H NMR (CDCl3):
d
(ppm) 3.61–3.68 (m, 8H, CH2 (8, 9, 11, and 12)), 4.11 (t, J ¼
5.6 Hz, 4H, CH2 (6) and CH2 (14)), 4.33 (t, J ¼ 5.6 Hz, 4H,
CH2 (5) and CH2 (15)), 7.04 (d, J ¼ 8.6 Hz, 2H, 6-H), 7.13
(dd, J ¼ 7.5 Hz, 2H, 4-H), 7.45 (dd, J ¼ 7.8 Hz, 2H, 5-H),
8.53 (d, J ¼ 8.5 Hz, 2H, 3-H). 13C NMR (CDCl3): d (ppm)
60.3 (CH2 (5) and CH2 (15)), 61.4 (CH2 (6) and CH2 (14)),
63.1 (CH2 (8) and CH2 (12)), 64.0 (CH2 (9) and CH2 (11)),
108.8 (C6), 115.4 (C4), 123.1 (C2), 128.72 (C3), 135.0 (C5),
153.4 (C7), 165.5 (C1-oxadiazole). MALDI-TOF-MS: m/z 413
(M þ 1).
´
[5] Lebrini, M.; Bentiss, F.; Lagrenee, M. J Heterocyclic Chem
2004, 41, 419.
[6] Lebrini, M.; Bentiss, F.; Vezin, H.; Wignacourt, J. P.;
´
Roussel, P.; Lagrenee, M. Heterocycles 2005, 65, 2847.
[7] Zhou, J. M.; Hua, W. T.; Yang, Q. C. Gaodeng Xuexiao
Huaxue Xuebao 1996, 17, 1721.
[8] (a) Perreux, L.; Loupy, A. Tetrahedron 2001, 57, 9199;
(b) Chaouchi, M.; Loupy, A.; Marque, S.; Petit, A. Euro J Org Chem
2002, 7, 1278.
2,3,20,21-Dibenzo-4,7,10,13,16,19,25-heptaoxa-23,24-diaza-
1
bicyclo[20.2.1]pentacosa-22,24-diene (2d). H NMR (CDCl3):
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet